Dr. Anat Globerson Levin

12/2013-present – Lab. Manager and senior scientist, Immunology Research, Tel Aviv medical center

12/2013-present scientific consultant, The Weizmann Institute of Science
03/2013-12/2013 - senior intern, The Weizmann Institute of Science
2003 - Teva Pharmacetical Industries Ltd. 
Researcher – Analytical Chemistry dept. at the R&D section.
2001 -Tel-Aviv University Department of molecular microbiology and biotechnology
Research project - Studies of the mTOR pathway in Yeast at the laboratory of Dr. Martin Kupiec.

• Globerson-Levin A, Waks T, Eshhar Z: Elimination of Progressive Mammary Cancer by Repeated Administrations of Chimeric Antigen Receptor Modified T Cells, Molecular therapy 22, 1029-1038, (2014).
• Shepshelovich J, Goldstein-Magal L, Globerson A, Yen PM, Rotman-Pikielny P, Hirschberg K: Protein synthesis inhibitors and the chemical chaperone TMAO reverse endoplasmic reticulum perturbation induced by overexpression of the iodide transporter pendrin. J Cell Sci 2005, 118:1577-1586.

• Zupančič E, Curato C, Kim JS, Yeini E, Porat Z, Viana AS, Globerson-Levin A, Waks T, Eshhar Z, Moreira JN, Satchi-Fainaro R, Eisenbach L, Jung S, Florindo HF. Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine. 2018 Jan 3. pii: S1549-9634(17)30589-0.

• Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, Lau J, Yu SF, Mizraji G, Globerson Levin A, Sliwkowski MX, Levitzki A.HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment, Cancer Immunol Res. 2016 Aug;4(8):688-97

• Z Eshhar, T Waks, A Globerson-Levin, D Blat , CAR mediated redirection of Teff and Treg cells for the treatment of cancer and auto-inflammation ‏The Journal of Immunology May 1, 2013, 190 (1), Supplement), 177.3-177.